Latest Senile plaques Stories

Close family members of people with Alzheimer's disease are more than twice as likely as those without a family history to develop silent buildup of brain plaques associated with Alzheimer's disease, according to researchers at Duke Medicine. The study, published online in the journal PLOS ONE on April 17, 2013, confirms earlier findings on a known genetic variation that increases one's risk for Alzheimer's, and raises new questions about other genetic factors involved in the disease that...

INDIANAPOLIS, Jan. 30, 2013 /PRNewswire/ -- Leading medical experts in the fields of imaging, neurology and dementia came together today to present evidence supporting the clinical utility of beta-amyloid imaging agents, such as Amyvid(TM) (Florbetapir F 18 Injection), during a public hearing held by the Centers for Medicare & Medicaid Services (CMS), known as a Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting. The CMS panel voted "low to...

Researchers at Washington University School of Medicine in St. Louis have found a key difference in the brains of people with Alzheimer's disease and those who are cognitively normal but still have brain plaques that characterize this type of dementia. "There is a very interesting group of people whose thinking and memory are normal, even late in life, yet their brains are full of amyloid beta plaques that appear to be identical to what's seen in Alzheimer's disease," says David L. Brody,...

INDIANAPOLIS, Oct. 19, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced they received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe, recommending approval of Amyvid (Florbetapir F 18) solution for injection as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the...

A new study shows that having a high amount of beta amyloid or "plaques" in the brain associated with Alzheimer's disease may cause steeper memory decline in mentally healthy older people than does having the APOE ɛ4 allele, also associated with the disease. The study is published in the October 16, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology. "Our results show that plaques may be a more important factor in determining which people are at...

Connie K. Ho for redOrbit.com – Your Universe Online Getting the right amount of sleep is more important than ever, as sleep is thought to have important health effects for individuals. In particular, a study by researchers at Washington University School of Medicine in St. Louis involving laboratory mice found that sleep disruption could be an early sign of Alzheimer’s disease. In the project, the scientists worked with a mouse model and discovered that the first indicators of...

HOFFMAN ESTATES, Ill., April 10, 2012 /PRNewswire/ -- Siemens Healthcare (NYSE: SI) is the first company worldwide to announce a complete integrated diagnostic imaging solution proposed for the detection of amyloid plaques -- one of the necessary pathological features of Alzheimer's disease(1,2,3) -- in the living brain. The latest elements of Siemens' integrated solution came today with the company's U.S. Food and Drug Administration (FDA) 510(k) application for its syngo(®).PET...

A single traumatic brain injury may prompt long-term neurodegeneration, Penn study showsYears after a single traumatic brain injury (TBI), survivors still show changes in their brains. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania suggest that Alzheimer's disease-like neurodegeneration may be initiated or accelerated following a single traumatic brain injury, even in young adults.Over 1.7 million Americans suffer a traumatic brain injury...

(Ivanhoe Newswire) "“ The little-studied amyloid peptide may be promoting Alzheimer's disease (AD), according to this study. Their findings show that the peptide is more abundant, more neurotoxic, and exhibits a higher propensity to aggregate than other agents studied earlier.An irreversible, progressive brain disease affecting millions worldwide, Alzheimer's disease is devastating for its victims, robbing them of their memory and cognitive skills and ultimately of their lives. Even after...

Highly aggregative and neurotoxic amyloid peptide A-beta-43 points the way to new approaches for AD diagnosis and treatmentResearchers at the RIKEN Brain Science Institute (BSI) and their collaborators have shed light on the function of a little-studied amyloid peptide in promoting Alzheimer's disease (AD). Their surprising findings reveal that the peptide is more abundant, more neurotoxic, and exhibits a higher propensity to aggregate than amyloidogenic agents studied in earlier research,...